1 – 7 of 7
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
All-cause and AIDS-related mortality among people with HIV across Europe from 2001 to 2020 : impact of antiretroviral therapy, tuberculosis and regional differences in a multicentre cohort study
(
- Contribution to journal › Article
- 2021
-
Mark
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months
(
- Contribution to journal › Article
- 2018
-
Mark
Protease Inhibitors or NNRTIs as First-Line HIV-1 Treatment in West Africa (PIONA) : A Randomized Controlled Trial
(
- Contribution to journal › Article
- 2016
-
Mark
Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
(
- Contribution to journal › Article
-
Mark
Differential effects of sex in a West African cohort of HIV-1, HIV-2, and HIV-1/2 infected patients: Men are worse off.
(
- Contribution to journal › Article
-
Mark
Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
2016) In Journal of the Pediatric Infectious Diseases Society(
- Contribution to journal › Article
- 2012
-
Mark
A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix (R) in subjects aged 11-17 years: An open, randomised, controlled trial
(
- Contribution to journal › Article